Ledipasvir/sofosbuvir for treatment-naive and treatment-experienced Chinese patients with genotype 1 HCV: an open-label, phase 3b study

Hepatology International

Volumn 12, Issue 2, 2018, Pages 126-132

  Wei, Lai ^a   Xie, Qing ^b   Hou, Jin Lin ^c   Tang, Hong ^d   Ning, Qin ^e   Cheng, Jun ^f   Nan, Yuemin ^g   Zhang, Lunli ^h   Li, Jun ⁱ   Jiang, Jianning ^j   McNabb, Brian ^k   Zhang, Fangqiu ^k   Camus, Gregory ^k   Mo, Hongmei ^k   Osinusi, Anu ^k   Brainard, Diana M ^k   Gong, Guozhong ^l   Mou, Zhuangbo ^m   Wu, Shanming ⁿ   Wang, Guiqiang ^o   Hu, Peng ^p   Gao, Yanhang ^q   Jia, Jidong ^r   Duan, Zhongping ^s   more..

^a PEKING UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

^c SOUTHERN MEDICAL UNIVERSITY   (China)

^d SICHUAN UNIVERSITY   (China)

^e HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^f CAPITAL MEDICAL UNIVERSITY   (China)

^g HEBEI MEDICAL UNIVERSITY   (China)

^h NANCHANG UNIVERSITY   (China)

ⁱ THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^j FIRST AFFILIATED HOSPITAL OF GUANGXI MEDICAL UNIVERSITY   (China)

^k GILEAD SCIENCES   (United States)

^l CENTRAL SOUTH UNIVERSITY   (China)

^m JINAN INFECTIOUS DISEASE HOSPITAL   (China)

ⁿ SHANGHAI PUBLIC HEALTH CLINICAL CENTER   (China)

^o PEKING UNIVERSITY FIRST HOSPITAL   (China)

^p THE SECOND AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

^q THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

^r CAPITAL MEDICAL UNIVERSITY   (China)

^s CAPITAL MEDICAL UNIVERSITY   (China)

more..

Author keywords

China; Genotype 1; Hepatitis C virus; Ledipasvir; Single tablet regimen; Sofosbuvir

Indexed keywords

LEDIPASVIR PLUS SOFOSBUVIR; ANTIVIRUS AGENT; BENZIMIDAZOLE DERIVATIVE; FLUORENE DERIVATIVE; LEDIPASVIR, SOFOSBUVIR DRUG COMBINATION; URIDINE PHOSPHATE; VIRUS RNA;

ADULT; AGED; ARTICLE; CHINESE; CHRONIC HEPATITIS C; COUGHING; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GENOTYPE; HUMAN; HYPERGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; UPPER RESPIRATORY TRACT INFECTION; VIRAL RESPIRATORY TRACT INFECTION; ANALOGS AND DERIVATIVES; ANTIVIRAL RESISTANCE; CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG EFFECT; MIDDLE AGED; PATIENT SAFETY; TABLET; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; AGED; ANTIVIRAL AGENTS; BENZIMIDAZOLES; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, VIRAL; FEMALE; FLUORENES; HEPATITIS C, CHRONIC; HUMANS; MALE; MIDDLE AGED; PATIENT SAFETY; RNA, VIRAL; TABLETS; TREATMENT OUTCOME; URIDINE MONOPHOSPHATE; YOUNG ADULT;

EID: 85045148689     PISSN: 19360533     EISSN: 19360541     Source Type: Journal    
DOI: 10.1007/s12072-018-9856-z     Document Type: Article

References (27)

1. Polaris Observatory HCVC. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2017;2:161–176.
2. Rao HY, Li H, Chen H, Shang J, Xie Q, Gao Z-L, Li J, et al. Real-world treatment patterns and clinical outcomes of HCV treatment-naive patients in China: an interim analysis from the CCgenos study. J Gastroenterol Hepatol. 2017;32:244–252.
3. ® (peginterferon alfa-2a) Injection for Subcutaneous Use. U.S. Prescribing Information. Nutley; 2015 (Revised March)
4. Omata M, Kanda T, Wei L, Yu M-L, Chuang W-L, Ibrahim A, Lesmana CRA, et al. APASL consensus statements and recommendation on treatment of hepatitis C. Hep Intl. 2016;10:702–726.
5. Jakobsen JC, Nielsen EE, Feinberg J, Katakam KK, Fobian K, Hauser G, Poropat G, et al. Direct-acting antivirals for chronic hepatitis C. Cochrane Database Syst Rev. 2017
6. DAKLINZA, Bristol-Myers Squibb (Singapore) Pte. Limited. DAKLINZA (daclatasvir) Tablets 60 mg. Chinese Prescribing Information. Version 1 [Chinese]. Beijng; 2017 (Approval April)
7. SUNVEPRA™, Bristol-Myers Squibb (Singapore) Pte. Limited. SUNVEPRA™ (asunaprevir) Soft Capsules 100 mg. Chinese Prescribing Information. Version 1 [Chinese]. Beijng; 2017 (Approval April)
8. ® (sofosbuvir) 400 mg Tablets. Chinese Package Insert [English]. Cork; 2017 (Revised: 20 September)
9. Wei L, Zhang M, Xu M, Chuang WL, Lu W, Xie W, Jia Z, et al. A Phase 3, open-label study of daclatasvir plus asunaprevir in asian patients with chronic hepatitis C virus genotype 1b infection who are Ineligible for or Intolerant to interferon Alfa therapies with or without ribavirin. J Gastroenterol Hepatol. 2016;31:1860–1867.
10. ® (ribavirin) Tablets, for oral use. U.S. Prescribing Information; 2015 (Revised August)
11. Afdhal N, Reddy KR, Nelson DR, Lawitz E, Gordon SC, Schiff E, Nahass R, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014;370:1483–1493.
12. Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, Romero-Gomez M, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014;370:1889–1898.
13. Kowdley KV, Gordon SC, Reddy KR, Rossaro L, Bernstein DE, Lawitz E, Shiffman ML, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med. 2014;370:1879–1888.
14. Kowdley KV, Sundaram V, Jeon CY, Qureshi K, Latt NL, Sahota A, Lott S, et al. Eight weeks of ledipasvir/sofosbuvir is effective for selected patients with genotype 1 hepatitis C virus infection. Hepatology. 2017;65:1094–1103.
15. Terrault NA, Zeuzem S, Di Bisceglie AM, Lim JK, Pockros PJ, Frazier LM, Kuo A, et al. Effectiveness of ledipasvir-sofosbuvir combination in patients with hepatitis C virus infection and factors associated with sustained virologic response. Gastroenterology. 2016;151(1131–1140):e1135.
16. Clopper CJ, Pearson ES. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika. 1934;26:404–413.
17. Guo X, Zhao Z, Xie J, Cai Q, Zhang X, Peng L, Gao Z. Prediction of response to pegylated-interferon-alpha and ribavirin therapy in Chinese patients infected with different hepatitis C virus genotype. Virol J. 2012;9:123.
18. Liu CH, Liu CJ, Lin CL, Liang CC, Hsu SJ, Yang SS, Hsu CS, et al. Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial. Clin Infect Dis. 2008;47:1260–1269.
19. Mizokami M, Yokosuka O, Takehara T, Sakamoto N, Korenaga M, Mochizuki H, Nakane K, et al. Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial. Lancet Infect Dis. 2015;15:645–653.
20. Lim YS, Ahn SH, Lee KS, Paik SW, Lee YJ, Jeong SH, Kim JH, et al. A phase IIIb study of ledipasvir/sofosbuvir fixed-dose combination tablet in treatment-naive and treatment-experienced Korean patients chronically infected with genotype 1 hepatitis C virus. Hepatol Int. 2016;10:947–955.
21. Chuang WL, Chien RN, Peng CY, Chang TT, Lo GH, Sheen IS, Wang HY, et al. Ledipasvir/sofosbuvir fixed-dose combination tablet in Taiwanese patients with chronic genotype 1 hepatitis C virus. J Gastroenterol Hepatol. 2016;31:1323–1329.
22. Chayama K, Imamura M, Hayes CN. Hepatitis C virus treatment update—a new era of all-oral HCV treatment. Adv Dig Med. 2016;3:153–160.
23. Zeuzem S, Mizokami M, Pianko S, Mangia A, Han K-H, Martin R, Svarovskaia E, et al. NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: prevalence and effect on treatment outcome. J Hepatol. 2017;66:910–918.
24. ® (ledipasvir and sofosbuvir) tablets, for oral use. US Prescribing Information. Foster City; 2017 (Revised: April)
25. ® (ledipasvir and sofosbuvir) 90 mg/400 mg tablets for oral use. Summary of Product Characteristics (SmPC). Cambridge; 2017 (Revised June)
26. Ren L, Gonzalez R, Wang Z, Xiang Z, Wang Y, Zhou H, Li J, et al. Prevalence of human respiratory viruses in adults with acute respiratory tract infections in Beijing, 2005–2007. Clin Microbiol Infect. 2009;15:1146–1153.
27. Yu X, Lu R, Wang Z, Zhu N, Wang W, Julian D, Chris B, et al. Etiology and clinical characterization of respiratory virus infections in adult patients attending an Emergency Department in Beijing. PLoS One. 2012;7:e32174.